Updates on Palliative Medicine in the COVID-19 Era

Varrassi, Giustino; Rekatsina, Martina

doi:10.3390/jcm11020315

Cited by 4 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic pain patients have been disproportionately impacted by the pandemic [16]. Chronic pain has been described as a multidimensional biopsychosocial phenomenon involving the complex interplay of biological, psychological, and social factors [17].…”

Section: Painful Syndromes In Covid-19mentioning

confidence: 99%

Pain Management and COVID-19: A Latin American Perspective

Guerrero¹,

Castromán²,

Quiroga³

et al. 2022

Cureus

Self Cite

View full text Add to dashboard Cite

Vaccinations and therapeutics have been developed for COVID-19, but vaccine uptake varies markedly among countries. Public health responses have also varied, in particular, with lockdown efforts and school closing. All over the world, the pandemic exposed healthcare and economic weaknesses. COVID-19 exacerbated mental health issues by exposing the population to prolonged periods of fear, anxiety, financial stress, psychological uncertainties, and sometimes isolation from even family and friends. Chronic pain patients have been disproportionately affected. The pandemic-associated stresses may have exacerbated their already painful symptoms while at the same time interrupting their access to care. The ramifications of the COVID-19 post-viral syndrome ("long are not yet known. COVID-19 viral infection has been associated with neuropathic pain symptoms. Tele-triage and telehealth applications can help manage chronic pain patients in the COVID-19 era, but many interventional procedures, injections, or other treatments have been delayed. The role of palliative care for patients with terminal cases of infection must be re-examined. Palliative care is a relatively new medical specialty and allows terminally ill patients to die in as much comfort and peace as can be afforded to them. More training in palliative care for all clinicians is urgently needed. COVID-19 exposed much that is wrong or weak or inadequate in our healthcare systems, but it also allowed us to embrace new technologies and develop better systems to manage the challenge of a pandemic.

show abstract

Section: Painful Syndromes In Covid-19mentioning

confidence: 99%

Pain Management and COVID-19: A Latin American Perspective

Guerrero¹,

Castromán²,

Quiroga³

et al. 2022

Cureus

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since the beginning of the COVID-19 pandemic, clinicians and researchers have explored the use and roles of general and specialist palliative care (PC) in COVID-19 patients [ 9 ]. While all medical professions and disciplines provide general PC, specialist PC (sPC) is provided by a multiprofessional sPC team.…”

Section: Introductionmentioning

confidence: 99%

Specialist Palliative Care Consultations in COVID-19 Patients in the ICU—A Retrospective Analysis of Patient Characteristics and Symptoms at a German University Hospital

Tenge

Brimah

Schlieper

et al. 2022

JCM

View full text Add to dashboard Cite

COVID-19 patients who may require invasive therapeutic procedures such as extracorporeal membrane oxygenation (ECMO) have high symptom burden and in-hospital mortality. In addition, awake patients on ECMO are new in the intensive care unit (ICU) setting. Inpatient specialist palliative care (sPC) provides support such as symptom control on a physical, psychosocial and spiritual level. The field of sPC in COVID-19 patients is still new and important to investigate. We aim to analyze sPC of COVID-19 patients in the ICU with regard to patient characteristics and symptoms from a palliative care perspective. We conducted a retrospective analysis (03/2020–04/2021) and identified 51 ICU patients receiving sPC. The statistical analysis included descriptive statistics and comparisons of symptoms. The first sPC contact of patients (mean age 69.5 years, 62.7% male) was around 14 days after COVID-19 confirmation, and 43% were treated with ECMO therapy. The baseline symptom burden was high with a focus on weakness (100%), tiredness (98%), dyspnea (96%) and family burden (92%). The symptom intensity significantly decreased during the time period of sPC and COVID-19 treatment (t(99) = 3.119, p = 0.003, d = 0.437). These results help intensivists and sPC clinicians to identify symptoms and the need for sPC in COVID-19 patients. However, studies with prospective and controlled designs need to follow.

show abstract

“…Various symptoms, ranging from fever, malaise, cough, shortness of breath, and, in severe cases, severe pneumonia, have been reported (Huang et al, 2020 ). In several countries, drugs like palliatives for the respiratory syndrome are being used for limited COVID‐19 treatment (Gavriatopoulou et al, 2021 ; Varrassi & Rekatsina, 2022 ). Recently, Pfizer's Paxlovid has received emergency use authorization from the FDA.…”

Section: Introductionmentioning

confidence: 99%

Low molecular weight chitooligosaccharide inhibits infection of SARS-CoV-2 in vitro

Jang

Lee

Jung

et al. 2022

Journal of Applied Microbiology

View full text Add to dashboard Cite

Aims:The discovery of antiviral substances to respond to COVID-19 is a global issue, including the field of drug development based on natural materials. Here, we showed that chitosan-based substances have natural antiviral properties against SARS-CoV-2 in vitro. Methods and Results:The molecular weight of chitosan-based substances was measured by the gel permeation chromatography analysis. In MTT assay, the chitosan-based substances have low cytotoxicity to Vero cells. The antiviral effect of these substances was confirmed by quantitative viral RNA targeting the RdRp and E genes and plaque assay. Among the substances tested, low molecular weight chitooligosaccharide decreased the fluorescence intensity of SARS-CoV-2 nucleocapsid protein of the virus-infected cells in a dose-dependent manner. Conclusions:In conclusion, the chitooligosaccharide, a candidate for natural treatment, has antiviral effects against the SARS-CoV-2 virus in vitro. Significance and Impact of Study:In this study, it was suggested for the first time that chitosan-based substances such as chitooligosaccharide can have an antiviral effect on SARS-CoV-2 in vitro.

show abstract

Updates on Palliative Medicine in the COVID-19 Era

Abstract: The advances in knowledge in the field of pain medicine in the last half century have recently been reported from both the scientific and the social points of view [...]

Cited by 4 publications

References 30 publications

Pain Management and COVID-19: A Latin American Perspective

Pain Management and COVID-19: A Latin American Perspective

Specialist Palliative Care Consultations in COVID-19 Patients in the ICU—A Retrospective Analysis of Patient Characteristics and Symptoms at a German University Hospital

Low molecular weight chitooligosaccharide inhibits infection of SARS-CoV-2 in vitro

Contact Info

Product

Resources

About